AK104 plus TACE for resectable liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an immunotherapy drug (AK104) to a standard liver cancer treatment (TACE) helps prevent the cancer from coming back after surgery. It is for people with early-stage liver cancer that can be surgically removed and who have a high risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your liver cancer can be surgically removed and is at an early or intermediate stage (BCLC A or B).
- You have not had any prior treatment for your liver cancer.
- Your cancer has certain features that make it more likely to come back, such as more than one tumor, a tumor larger than 5 cm, a high AFP blood level, or signs of tumor invasion into blood vessels on an MRI.
- You are generally active and able to care for yourself (ECOG 0-1) and your liver function is good (Child-Pugh class A).
- Your blood counts and organ function are within required ranges, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
This trial tests whether taking icariin soft capsules along with a liver-directed treatment called TACE can help prevent liver cancer from coming back after surgery or ablation. It is for people who have had their tumor removed but still have risk factors that make recurrence more likely.
This trial tests combining a targeted medicine (Icaritin) with a procedure that delivers chemotherapy directly to the liver (TACE) after surgery. It is for people with liver cancer who have a high chance of the cancer coming back, to see if this treatment helps prevent recurrence.
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
This trial tests a new immunotherapy drug (ivonescimab) combined with TACE (a procedure that blocks blood flow to the tumor) for people with liver cancer that cannot be surgically removed. It aims to see if adding the immunotherapy can help control the cancer better than TACE alone.
This study tests a new drug called AK112 (a combination antibody targeting two proteins that help tumors grow) after surgery for liver cancer that has a high chance of returning. The goal is to see if it can prevent the cancer from coming back.
Hear when a new Resectable Hepatocellular Carcinoma With High Risk of Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.